HRTX - Heron Therapeutics Inc
IEX Last Trade
1.92
-0.010 -0.521%
Share volume: 1,423,635
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.93
-0.01
-0.52%
Fundamental analysis
24%
Profitability
25%
Dept financing
7%
Liquidity
66%
Performance
16%
Performance
5 Days
-1.03%
1 Month
-31.32%
3 Months
-44.06%
6 Months
-28.52%
1 Year
14.20%
2 Year
-50.77%
Key data
Stock price
$1.92
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.50 - $3.93
52 WEEK CHANGE
$0.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Barry Quart
Region: US
Website: http://www.herontx.com/
Employees: 283
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.herontx.com/
Employees: 283
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Recent news